ALTME Share Price Performance
€0.064
-0.01 (-16.45%)
Price €0.064
Share Pricen/a
TME Pharma N.V. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ALTME Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
TME Pharma N.V. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.049
- 100.00%
- -16,948.15%
- -301.8%
About ALTME
- Founded
- 1997
- Employees
- 12
- CEO
- WebsiteView website
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
